Colorectal cancer with potentially resectable hepatic metastases: optimizing treatment

被引:0
|
作者
Worni, Mathias [1 ]
Shah, Kevin N. [1 ]
Clary, Bryan M. [1 ]
机构
[1] Duke Univ, Med Ctr, Div Surg Oncol, Durham, NC 27710 USA
来源
ONCOLOGY IN CLINICAL PRACTICE | 2014年 / 10卷 / 05期
关键词
colorectal cancer; gastrointestinal cancers; hepatic metastases; future liver remnant; oncology;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Colorectal cancer is a common malignancy and often presents with synchronous or metachronous distant spread. For patients with hepatic metastases, resection is the principal curative option. Liberalization of the indications for hepatic resection has introduced a number of challenges related to the size, distribution, and number of metastases as well as the condition of the future liver remnant. Advances in systemic therapy have solidified its role as both an important adjunct to surgery and also for many patients as a mechanism to facilitate resection. In patients whose disease is marginally resectable as a consequence of the distribution of hepatic lesions that precludes complete resection or out of concern for the future liver remnant, a number of strategies have been advocated, including prehepatectomy systemic therapy, staged surgical approaches, ablative technologies, and preoperative portal vein embolization. It is the purpose of this review to discuss ways in which to optimize the treatment of patients with potentially resectable disease, specifically those who are judged to have "borderline" resectable situations.
引用
收藏
页码:270 / 282
页数:13
相关论文
共 50 条
  • [31] Resection of hepatic metastases from colorectal cancer
    Nuzzo, G
    Giuliante, F
    Giovannini, I
    Tebala, GD
    Clemente, G
    Vellone, M
    HEPATO-GASTROENTEROLOGY, 1997, 44 (15) : 751 - 759
  • [32] Surgical Management of Hepatic Metastases of Colorectal Cancer
    Smith, J. Joshua
    D'Angelica, Michael I.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2015, 29 (01) : 61 - +
  • [34] Use of Bevacizumab in the Management of Potentially Resectable Colorectal Liver Metastases: Safety, Pathologic Assessment and Benefit
    Innominato, Pasquale F.
    Adam, Rene
    CURRENT COLORECTAL CANCER REPORTS, 2016, 12 (04) : 208 - 216
  • [35] Treatment of hepatic metastases from colorectal cancer: Many doubts, some certainties
    Biasco, G.
    Derenzini, E.
    Grazi, GL.
    Ercolani, G.
    Ravaioli, M.
    Pantaleo, M. A.
    Brandi, G.
    CANCER TREATMENT REVIEWS, 2006, 32 (03) : 214 - 228
  • [36] Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment
    Kun-Ming Chan
    Jy-Ming Chiang
    Chen-Fang Lee
    Ming-Chin Yu
    Wei-Chen Lee
    Jinn-Shiun Chen
    Jeng-Yi Wang
    World Journal of Surgical Oncology, 9
  • [37] Management of resectable colorectal lung metastases
    Moorcraft, Sing Yu
    Ladas, George
    Bowcock, Anne
    Chau, Ian
    CLINICAL & EXPERIMENTAL METASTASIS, 2016, 33 (03) : 285 - 296
  • [38] Transarterial Chemoembolization Using DEBIRI for Treatment of Hepatic Metastases from Colorectal Cancer
    Narayanan, Govindarajan
    Barbery, Katuzka
    Suthar, Rekha
    Guerrero, Gabriella
    Arora, Geetika
    ANTICANCER RESEARCH, 2013, 33 (05) : 2077 - 2083
  • [39] Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment
    Chan, Kun-Ming
    Chiang, Jy-Ming
    Lee, Chen-Fang
    Yu, Ming-Chin
    Lee, Wei-Chen
    Chen, Jinn-Shiun
    Wang, Jeng-Yi
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2011, 9
  • [40] Management of resectable colorectal lung metastases
    Sing Yu Moorcraft
    George Ladas
    Anne Bowcock
    Ian Chau
    Clinical & Experimental Metastasis, 2016, 33 : 285 - 296